Crossmark

Angiotensin in ECMO patients with refractory shock

Crossref DOI link: https://doi.org/10.1186/s13054-018-2225-4

Published Online: 2018-11-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ostermann, Marlies http://orcid.org/0000-0001-9500-9080
Boldt, David W.

Harper, Michael D.

Lim, George W.

Gunnerson, Kyle
License Information

Text and Data Mining valid from 2018-11-01
More Information

Article History

Received: 29 September 2018

Accepted: 10 October 2018

First Online: 1 November 2018

Ethics approval and consent to participate

: The case series includes patients who participated in the ATHOS-3 study or received angiotensin II in the context of a compassionate treatment program. The ATHOS-3 study was fully approved by an independent research ethics committee.

: As part of the ATHOS-3 study, patients gave consent for their data and results to be published in an anonymized format.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.